Wockhardt, a global pharmaceutical and biotechnology company, has filed its fast-acting insulin analog, Aspart injection (ASPARAPIDTM), with the Drugs Controller General of India (DCGI). This development marks a significant milestone in Wockhardt’s efforts to tackle the growing diabetes crisis in India and globally. Diabetes affects over 77 million people in India and more than 537 million worldwide, a number expected to rise to 643 million by 2030.
The Aspart insulin injection, developed indigenously by Wockhardt, showcases the company’s expertise in research, development, and manufacturing. The injection will be available in cartridges, vials, and prefilled disposable pens, providing greater flexibility for patients managing diabetes. The current market size for Aspart insulin in India is estimated at over INR 260 crore, with only two major players.
Dr. Habil Khorakiwala, Founder Chairman of Wockhardt, expressed pride in the company’s ability to develop and manufacture complex biosimilars, stating, “Our aim is to make world-class diabetes care accessible to patients in India and globally.”
Wockhardt is also working on other insulin analogs and GLP-1 agonists to further expand its diabetes care portfolio, offering more treatment options for managing the condition.